Access to CAR-T therapy will now be available to lymphoma patients
Australia’s Minister for Health, the Hon. Greg Hunt MP, announced today that access to the CAR T-cell therapy, tisagenlecleucel, will be expanded to include those battling particular types of highly aggressive blood cancers. Patients with relapsed or refractory diffuse large B-cell lymphoma, transformed follicular lymphoma, and primary mediastinal B-cell lymphoma that is not responding to conventional treatment may now access tisagenlecleucel. Just last year the therapy received approval and public funding to help paediatric patients living with forms of acute lymphoblastic leukaemia. Today’s announcement means that around 250 more patients can access the ground-breaking therapy, which harnesses a patient’s own T-cells to help fight the blood cancer.
In keeping with our ongoing commitment to progressing cutting-edge blood cancer therapies in the Australasian region, the ALLG is excited about the expansion of CAR T-cell therapies for lymphoma patients. Delaine Smith, ALLG CEO, who also leads the National Blood Cancer Taskforce’s Enabling Access Working Group said of the announcement, “Helping provide all Australians with expanded access to innovative treatments that are already available overseas is a high priority. The ALLG is currently working to launch new clinical trials in 2020 in the cell therapies area.”
“Furthermore, we congratulate the ALLG Members from the Peter MacCallum Cancer Centre for their roles in developing the therapy and for being named the Australian hub and global manufacturing centre for this type of CAR T-cell therapy,” Ms Smith added.
For a full list of open ALLG clinical trials, please visit: https://www.allg.org.au/clinical-trials-research/current-clinical-trials/